X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (371) 371
humans (300) 300
glucose (294) 294
diabetes (267) 267
endocrinology & metabolism (252) 252
diabetes mellitus, type 2 - drug therapy (219) 219
type 2 diabetes (217) 217
male (210) 210
diabetes mellitus (197) 197
sodium (196) 196
dextrose (172) 172
female (170) 170
hypoglycemic agents - therapeutic use (146) 146
sodium-glucose transporter 2 - antagonists & inhibitors (141) 141
animals (140) 140
middle aged (133) 133
dapagliflozin (110) 110
glucose transporter (108) 108
glucosides - therapeutic use (104) 104
insulin (102) 102
aged (100) 100
analysis (94) 94
diabetes mellitus, type 2 - blood (94) 94
sglt2 inhibitor (93) 93
double-blind (90) 90
hypoglycemic agents - adverse effects (86) 86
clinical trials (84) 84
treatment outcome (81) 81
sodium-glucose transporter 2 - metabolism (80) 80
blood pressure (78) 78
benzhydryl compounds - therapeutic use (77) 77
hypoglycemic agents (76) 76
care and treatment (73) 73
diabetes mellitus, type 2 - complications (73) 73
canagliflozin (71) 71
diabetes mellitus, type 2 - metabolism (70) 70
safety (70) 70
diabetes therapy (69) 69
rodents (69) 69
body weight (68) 68
metformin (68) 68
adult (67) 67
blood glucose - metabolism (66) 66
glucose - metabolism (66) 66
hyperglycemia (66) 66
patients (66) 66
empagliflozin (65) 65
hemoglobin (63) 63
risk factors (60) 60
glucose metabolism (59) 59
glucosides - adverse effects (59) 59
mellitus (58) 58
glycosylated hemoglobin (57) 57
sodium-glucose transporter 1 - metabolism (57) 57
blood glucose - drug effects (56) 56
mice (55) 55
double-blind method (54) 54
medical research (53) 53
metabolism (53) 53
glycemic control (52) 52
hypoglycemic agents - administration & dosage (52) 52
efficacy (51) 51
inhibitors (51) 51
benzhydryl compounds - adverse effects (48) 48
insulin resistance (48) 48
type-2 diabetes-mellitus (48) 48
sodium-glucose transporter 2 inhibitors - therapeutic use (47) 47
transporter (47) 47
glucosides - pharmacology (46) 46
hypoglycemia (46) 46
glycated hemoglobin a - metabolism (44) 44
hypoglycemic agents - pharmacology (44) 44
drug therapy (43) 43
kidneys (43) 43
type 2 diabetes mellitus (43) 43
cardiovascular diseases (42) 42
gene expression (41) 41
inadequate glycemic control (41) 41
multidisciplinary sciences (41) 41
benzhydryl compounds - pharmacology (40) 40
blood sugar (40) 40
medicine (40) 40
drug therapy, combination (39) 39
original (39) 39
research article (39) 39
science (39) 39
sglt2 inhibitors (39) 39
heart diseases (38) 38
mortality (38) 38
physiology (38) 38
sodium-glucose transporter 1 - genetics (38) 38
glucosides - administration & dosage (37) 37
risk (37) 37
cardiovascular disease (36) 36
medicine, experimental (36) 36
rats (36) 36
internal medicine (35) 35
cardiac & cardiovascular systems (34) 34
complications and side effects (34) 34
medicine & public health (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cellular Physiology and Biochemistry, ISSN 1015-8987, 07/2017, Volume 42, Issue 4, pp. 1358 - 1365
Background: Cellular glucose uptake may involve either non-concentrative glucose carriers of the GLUT family or Na+-coupled glucose-carrier SGLT1, which... 
Spleen | coupled glucose transport | Glucose uptake | TNF-α and IL-12a | Liver | Lung | Bacterial clearance | Listeria infection | Survival | Kidney | Na+-coupled glucose transport | CELLS | PHYSIOLOGY | TRANSPORTERS | GRANULOCYTES | INCREASES | CANCER | TNF-alpha and IL-12a | HYPERGLYCEMIA | METABOLISM | GLUCOSE-TRANSPORTER-1 | GLUCOSE COTRANSPORTER SGLT1 | EXPRESSION | Lung - microbiology | RNA, Messenger - immunology | Liver - pathology | Spleen - immunology | Kidney - pathology | Interleukin-12 - genetics | Tumor Necrosis Factor-alpha - genetics | Kidney - immunology | Liver - microbiology | Male | Sodium-Glucose Transporter 1 - genetics | Spleen - microbiology | Sodium-Glucose Transporter 1 - deficiency | Liver - immunology | Biological Transport | Gene Expression - immunology | Listeriosis - immunology | Tumor Necrosis Factor-alpha - immunology | Spleen - pathology | Lung - pathology | Listeriosis - mortality | Interleukin-6 - genetics | Glucose - immunology | Listeriosis - genetics | Mice, Inbred C57BL | RNA, Messenger - genetics | Listeria monocytogenes | Bacterial Load | Mice, Knockout | Kidney - microbiology | Animals | Interleukin-12 - immunology | Interleukin-6 - immunology | Survival Analysis | Glucose - metabolism | Listeriosis - microbiology | Mice | Sodium-Glucose Transporter 1 - immunology | Lung - immunology | Bacterial infections | Laboratories | Infections | Metabolism | Kinases | Small intestine | Listeria | Granulocytes | Lymphocytes | Rodents | Cancer | Index Medicus
Journal Article
American Journal of Physiology - Cell Physiology, ISSN 0363-6143, 08/2008, Volume 295, Issue 2, pp. 475 - 489
Previously, we characterized localization of Na+-glucose cotransporter SGLT1 (Slc5a1) in the rat kidney using a polyclonal antibody against the synthetic... 
Brain | Proximal tubule | Liver | Salivary gland | Sex differences | Myenteric plexus | Small intestine | Enteroendocrine cells | Kidney | LOCALIZATION | PHYSIOLOGY | liver | brain | IDENTIFICATION | FAMILY | CELL BIOLOGY | enteroendocrine cells | salivary gland | kidney | TRANSPORT WATER | small intestine | ABSORPTION | proximal tubule | NA+/GLUCOSE COTRANSPORTER | EXPRESSION | sex differences | myenteric plexus | AQUAPORINS | BILE | Colon - cytology | Stomach - chemistry | Rats, Wistar | Microvilli - chemistry | Colon - chemistry | Kidney Tubules, Proximal - chemistry | Male | Stomach - metabolism | Salivary Glands - cytology | Sodium-Glucose Transporter 1 - genetics | Jejunum - metabolism | Brain - metabolism | Cell Membrane - chemistry | Nephrons - cytology | Kidney - metabolism | Castration | Antibodies - immunology | Female | Cell Membrane - metabolism | Jejunum - cytology | Nephrons - chemistry | Sodium-Glucose Transporter 1 - metabolism | Intestine, Small - chemistry | Kidney Tubules, Proximal - cytology | Brain - cytology | Gene Expression | Ovariectomy | Liver - metabolism | Rats | Jejunum - chemistry | Kidney - cytology | Blotting, Western | Colon - metabolism | Liver - chemistry | Salivary Glands - chemistry | Immunohistochemistry - methods | Animals | Intestine, Small - cytology | Microvilli - metabolism | Kidney Tubules, Proximal - metabolism | Sex Factors | Stomach - cytology | Kidney - chemistry | Liver - cytology | Sodium-Glucose Transporter 1 - immunology | Intestine, Small - metabolism | Salivary Glands - metabolism | Nephrons - metabolism
Journal Article
Cellular Physiology and Biochemistry, ISSN 1015-8987, 09/2016, Volume 39, Issue 3, pp. 1209 - 1228
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, p. e54442
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patients with diabetes mellitus. SGLT2 inhibitors block... 
MATRIX | STIMULATION | MULTIDISCIPLINARY SCIENCES | DISEASE | HIGH GLUCOSE | GENE-EXPRESSION | PPAR-GAMMA AGONISTS | TRANSFORMING GROWTH FACTOR-BETA | Diabetes Mellitus - pathology | Epithelial Cells - metabolism | Gene Expression - drug effects | Diabetes Mellitus - genetics | Transcription Factor AP-1 - genetics | Epithelial Cells - drug effects | Humans | Diabetic Nephropathies - drug therapy | NF-kappa B - metabolism | Smad3 Protein - metabolism | Transcription Factor AP-1 - metabolism | Sodium-Glucose Transporter 1 - genetics | Smad3 Protein - genetics | Sodium-Glucose Transporter 1 - metabolism | Phosphorylation - drug effects | Interleukin-6 - metabolism | Transforming Growth Factor beta1 - pharmacology | Sodium-Glucose Transporter 2 - genetics | Collagen Type IV - metabolism | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Promoter Regions, Genetic | Diabetic Nephropathies - pathology | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Interleukin-6 - genetics | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Diabetes Mellitus - drug therapy | Diabetes Mellitus - metabolism | Toll-Like Receptor 4 - genetics | Diabetic Nephropathies - genetics | Epithelial Cells - pathology | Glucose - pharmacology | Toll-Like Receptor 4 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | NF-kappa B - genetics | Kidney Tubules, Proximal - metabolism | Collagen Type IV - genetics | Protein Binding | Benzhydryl Compounds - pharmacology | Kidney Tubules, Proximal - drug effects | Physiological aspects | Care and treatment | Genetic aspects | Research | Transforming growth factors | Diabetic nephropathies | Chromatin | Immunoprecipitation | Transforming growth factor-b | Interleukin | Clinical trials | Systematic review | Smad3 protein | Glucose | Kinases | Interleukin 6 | Proteins | Hyperglycemia | Rodents | Toll-like receptors | Collagen (type IV) | Hypoglycemic agents | Inhibition | Growth factors | Deoxyribonucleic acid--DNA | Immune system | Binding | Glucose transporter | Medical research | NF-κB protein | Secretion | Diabetes mellitus | Markers | Activator protein 1 | Blocking | Reabsorption | Inflammation | Gene expression | Glucose transport | Medicine | High mobility group proteins | Hospitals | Inhibitors | Nephropathy | Sodium | Fibrosis | Kidney diseases | Diabetes | Transporter | Adenosine triphosphatase | Kidney transplantation | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1988 - 1993
The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects... 
acute kidney injury | type 2 diabetes | MCP‐1 | SGLT‐2 | dapagliflozin | KIM‐1 | KIM-1 | MCP-1 | SGLT-2 | DIABETIC-NEPHROPATHY | HYPOXIA | DAMAGE | DECLINE | INFLAMMATION | DISEASE | ENDOCRINOLOGY & METABOLISM | KIDNEY | EMPAGLIFLOZIN | Inflammation Mediators - urine | Kidney Tubules - physiopathology | Biomarkers - urine | Humans | Kidney Glomerulus - physiopathology | Diabetes Mellitus, Type 2 - metabolism | Diabetic Nephropathies - immunology | Interleukin-6 - urine | Glomerular Filtration Rate - drug effects | Netherlands | Benzhydryl Compounds - adverse effects | Acute Kidney Injury - complications | Adult | Glucosides - therapeutic use | Acute Kidney Injury - immunology | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Kidney Tubules - immunology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Albuminuria - etiology | Double-Blind Method | Kidney Tubules - drug effects | Kidney Glomerulus - drug effects | Inflammation Mediators - blood | Renal Elimination - drug effects | Biomarkers - blood | Albuminuria - prevention & control | Acute Kidney Injury - prevention & control | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Diabetes Mellitus, Type 2 - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hepatitis A Virus Cellular Receptor 1 - metabolism | Kidney Glomerulus - immunology | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Albumin | Analysis | Immunoglobulin G | Excretion | Inflammation | Cell injury | Diabetes | Epidermal growth factor receptors | Brief Reports | Brief Report
Journal Article
Journal Article
by Liu, R and Wei, N and Guo, W and Qiang, O and Li, X and Ou, Y and Huang, W and Tang, C W
European Journal of Nutrition, ISSN 1436-6207, 4/2013, Volume 52, Issue 3, pp. 1067 - 1075
To investigate the role of octreotide, a somatostatin (SST) analog with anti-inflammatory effects, on the digestive and absorptive functions of jejunum in rats... 
Obesity | Chemistry | Nutrition | Rat | Octreotide | Maltase | Na + -dependent glucose transporter protein (SGLT-1) | Jejunal absorption | dependent glucose transporter protein (SGLT-1) | WEIGHT-LOSS | GUT MICROBIOTA | SUPPRESSION | Na+-dependent glucose transporter protein (SGLT-1) | FACTOR-ALPHA | CHILDREN | SYSTEMIC INFLAMMATION | TUMOR-NECROSIS-FACTOR | NUTRITION & DIETETICS | SOMATOSTATIN | ADAPTATION | EXPRESSION | Intestinal Mucosa - metabolism | Obesity - drug therapy | Obesity - immunology | Tumor Necrosis Factor-alpha - blood | Intestinal Absorption - drug effects | Male | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Intestinal Mucosa - drug effects | Sodium-Glucose Transporter 1 - genetics | Jejunum - metabolism | Jejunum - drug effects | Jejunum - ultrastructure | Intestinal Mucosa - immunology | Sodium-Glucose Transporter 1 - metabolism | Somatostatin - metabolism | Somatostatin - secretion | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Digestion - drug effects | Intestinal Mucosa - ultrastructure | Rats | Microvilli - immunology | Jejunum - immunology | Random Allocation | Octreotide - therapeutic use | Rats, Sprague-Dawley | Obesity - metabolism | Obesity - pathology | Gene Expression Regulation - drug effects | Microvilli - drug effects | Animals | Somatostatin - blood | Microvilli - metabolism | Microvilli - ultrastructure | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Gastrointestinal Agents - therapeutic use
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1361 - 1366
Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors reduce the risk of serious heart failure events in patients with type 2 diabetes, but little is known about... 
antidiabetic drug | cardiovascular disease | SGLT2 inhibitor | METABOLIC SYNDROME | BODY-WEIGHT | TYPE-2 DIABETIC-PATIENTS | EPICARDIAL FAT ACCUMULATION | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITOR | PLACEBO-CONTROLLED TRIAL | CARDIAC FIBROSIS | ADIPOSE-TISSUE | Kidney Tubules - physiopathology | Leptin - antagonists & inhibitors | Myocardium - immunology | Diabetic Cardiomyopathies - etiology | Obesity - immunology | Sodium-Glucose Transporter 2 - chemistry | Humans | Leptin - metabolism | Heart Failure - physiopathology | Renal Insufficiency - prevention & control | Diabetes Mellitus, Type 2 - metabolism | Diabetic Cardiomyopathies - physiopathology | Heart Failure - prevention & control | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Diabetes Mellitus, Type 2 - immunology | Myocardium - metabolism | Heart Failure - immunology | Diabetic Cardiomyopathies - prevention & control | Renal Insufficiency - complications | Intra-Abdominal Fat - drug effects | Kidney Tubules - metabolism | Diabetic Nephropathies - prevention & control | Heart Failure - etiology | Diabetes Mellitus, Type 2 - complications | Heart - physiopathology | Hypoglycemic Agents - therapeutic use | Intra-Abdominal Fat - immunology | Kidney Tubules - immunology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Kidney Tubules - drug effects | Obesity - complications | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Stroke Volume - drug effects | Diabetic Cardiomyopathies - complications | Obesity - physiopathology | Renal Insufficiency - metabolism | Intra-Abdominal Fat - metabolism | Obesity - metabolism | Diabetic Nephropathies - complications | Animals | Models, Biological | Heart - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Heart failure | Prevention | Type 2 diabetes | Leptin | Cardiac patients | Hypoglycemic agents | Glucose | Dextrose | Glucose transporter | Obesity | Phenotypes | Adipose tissue | Kidneys | Secretion | Diabetes mellitus | Clinical trials | Paracrine signalling | Renal tubules | Hypotheses | Sodium | Fibrosis | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases
Journal Article